patent.fyi
Applications  /  US 2026/0356824
United States Patent Application Publication

US 2026/0356824 A1

Published
Nov 12, 2026
Filed
May 31, 2024
Earliest date on the face
Jun 2, 2023
Classification
C07D 413/04
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Fluorine at the RA position

What ifWhat if fluorine occupies the RA position?
Claim language“RA is hydrogen”

A single fluorine atom forms a bond to the scaffold at the RA position. The bond introduces a local dipole without adding a rotatable bond.

1.2Carbon cage at ring B

What ifWhat if ring B is bicyclo[1.1.1]pentane-1,3-diyl?
Claim language“3-7 membered heterocyclylene”

The two scaffold fragments attach to opposite bridgehead carbons of the cage. Three methylene bridges hold the attachment vectors along a common axis.

1.3Alkyne at the ring C position

What ifWhat if an ethynylene linker connects the two fragments at the ring C position?
Claim language“Ring C is phenylene”

Each fragment bonds to one carbon of a carbon–carbon triple bond. The two sp-hybridized carbons hold the attachment bonds along a common axis.

1.6Carboxamide at an R1 site

What ifWhat if an R1 site carries a primary carboxamide?
Claim language“5-6 membered heteroaryl”

The scaffold bonds directly to the carbonyl carbon of —C(═O)NH2. The carbonyl oxygen accepts hydrogen bonds, and the amide NH groups donate them.

1.8Cyano at an R2 site

What ifWhat if an R2 site carries a cyano group?
Claim language“C1-C6 haloalkyl”

The scaffold bonds directly to the carbon of —C≡N. The triple bond gives the substituent a linear geometry, and the terminal nitrogen acts as a hydrogen-bond acceptor.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reference control for receptor assay kits

A characterized LPA1 inhibitor containing the two-ring arrangement serves as the inhibition control in a research assay kit. The kit supplies single-use inhibitor aliquots, a matching vehicle, and a lysophosphatidic acid challenge solution. Each assay plate compares agonist-stimulated wells containing the inhibitor with agonist-stimulated wells containing vehicle to measure the assay response range.

Component substitution

Tetrazole replaces the carboxyl group

A 1H-tetrazol-5-yl group replaces the carboxyl group at Q. The tetrazole attaches through its carbon atom to the scaffold atom that bears the carboxyl group in the reference compound. A matched pair uses the same rings, linker, and remaining substituents, and an LPA1 signaling assay measures the concentration-response curve of each compound.

Ether segment replaces the carbamate linker

A methylene ether segment, —CH₂O—, replaces a carbamate at X. The methylene end attaches to the scaffold atom that connects to the methylene of the reference carbamate, and the oxygen end attaches to the opposite scaffold atom. A matched pair retains the same rings and Q group for comparison in an LPA1 signaling assay.

Parameter or scale variation

Longer spacers in the carbamate linker

A three-member compound series uses one, two, or three methylene units immediately before the carbamate nitrogen in X. The rings, Q group, carbamate orientation, and nitrogen substituent stay fixed across the series. Each member runs in a 10-point, threefold dilution series against a fixed lysophosphatidic acid challenge in cells expressing LPA1.

Combination with existing systems

Perfused lung tissue model with receptor inhibition

A two-channel microfluidic device holds lung epithelial cells on one side of a porous membrane and lung fibroblasts in a collagen matrix on the other. The fibroblast-side perfusate delivers lysophosphatidic acid with either a two-ring LPA1 inhibitor or matching vehicle, and parallel channels receive vehicle without agonist to establish baseline response. Imaging measures fibroblast alpha-smooth muscle actin and collagen deposition after exposure.

Automated or data-driven variant

Automated concentration response profiling

A liquid handler dispenses scaffold variants across a multiwell plate containing cells that express LPA1 and a calcium-sensitive fluorescent dye. A fluorescence reader records signals before and after automated addition of a fixed lysophosphatidic acid concentration. Software normalizes peak responses to vehicle-treated wells with and without agonist, fits concentration-response curves, and reports half-maximal inhibitory concentrations when the measured responses bracket the midpoint.

Specific version of a part

Cyclohexyl at the R3 position

R3 is cyclohexyl, a saturated six-carbon ring attached through one ring carbon. The ring adopts chair conformations.

Para cyano substituent on phenyl

RE is 4-cyanophenyl, attached through carbon 1 of the benzene ring. A single —C≡N group bonds through its carbon to ring carbon 4.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 9,932,326 B2
Published
Apr 3, 2018
Filed
Nov 10, 2015
Class
C07D 403/14
Document BUS 10,179,778 B2
Published
Jan 15, 2019
Filed
Sep 27, 2013
Class
C07D 409/10
Claim 1
Document A
Document B
1.1RA is hydrogen, C1-C6 alkyl, or C1-C6 alkoxy
1.2Ring B is 3-7 membered heterocyclylene or 5-6 membered heteroarylene
If B is cyclic it is selected from phenyl and a six-membered heteroaromatic ring containing one, two, or three nitrogen atoms, a six-membered ring or a six-membered bridged or spiro-fused ring containing none, one, or two heteroatoms independently selected from N, O, and S, a five-membered heteroaromatic ring containing one, two, or three heteroatoms independently selected from N, O, and S, a five-membered ring containing none, one, or two heteroatoms independently selected f
A · US 9,932,326 B2 · ¶ 14
A, B, and C are each the same or different carbocyclic aryl or heteroaromatic groups (e.g., C6-14 carbocyclic aryl or heteroaromatic group having from 5 to 14 atoms, including 1-4 heteroatoms selected from O, S, and N, in the heteroaromatic ring system), each of which may be optionally substituted.
B · US 10,179,778 B2 · ¶ 34
1.3Ring C is phenylene or 5-6 membered heteroarylene
A is selected from phenyl and six-membered heteroaromatic rings containing one, two, or three nitrogen atoms;
A · US 9,932,326 B2 · ¶ 12
1.4m is 0 or 1
1.5n is 0, 1, 2, or 3
R is —(CX′X″)nC(═O)OR, wherein n is a positive integer, each X′ and X″ is independently a hydrogen or non-hydrogen substituent, and R′ is a non-hydrogen substituent; each T, each T′ and each T″ are the same or different non-hydrogen substituent, wherein either of T and T″ or T and T′ are capable of joining to form a ring; n, n′ and n″ are each independently 0, 1, 2, 3 or 4;
B · US 10,179,778 B2 · claim 7
1.6each R1 is independently selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, 3-7 membered heterocyclyl, and 5-6 membered heteroaryl
each R1 and R1′ are independently present or absent if present are independently selected from hydroxy, hydroxyalkyl, alkoxy(C1-6), alkoxyalkyl(C2-8), alkoxycarbonyl, alkyl(C1-8), arylalkoxycarbonyl, lower alkenyl (C2-6), lower alkynyl (C2-6), carboxy, halogen (F, Cl, Br, I), CF3, haloalkyl, N3, CN, N(R′)2, SR′, OCOR′, N(COR′)R′, N(COR′)COR′, SCOR′, S(O)2NR′2, S(O)2R′.
A · US 9,932,326 B2 · ¶ 37
1.7or two R1 together with the atoms to which they are attached forms a 5-8 membered heterocyclyl or 5-6 membered heteroaryl
R8 and R9, together with the carbon atom to which they are attached, form a five- or six-membered saturated ring optionally containing one or two heteroatoms selected from NRz, O, and S; wherein Rz is selected from hydrogen and alkyl;
A · US 9,932,326 B2 · ¶ 56
1.8each R2 is independently selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and halogen
R14 and R14′ are independently selected from halogen (F, Cl, Br, I), CF3, hydroxy, alkoxy (C1-6), aryl, 5-membered heteroaryl, lower alkyl (C1-6) or halo substituted aryl, aryl or halo substituted 5-membered heteroaryl, cyano, alkynyl (C2-6), alkoxyalkyl (C3-6), alkoxycarbonylalkyl, alkyl, arylalkoxycarbonyl, carboxy, haloalkyl, heterocyclylalkyl, hydroxyalkyl; and
A · US 9,932,326 B2 · ¶ 100
1.9R3 is selected from: (i) hydrogen, (ii) C1-C6 alkyl optionally substituted with 1-2 independently selected RE, (iii) C6-C10 aryl optionally substituted with hydroxyl, (iv) C5-C10 cycloalkyl, (v) 5-6 membered heteroaryl optionally substituted with phenyl, and (vi) 5-6 membered heterocyclyl optionally substituted with phenyl
each R10 and R11 are independently selected from H, alkylcarboxy amino, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylamino, alkylguanasyl, alkylaryl, aryl, arylalkenyl, arylalkoxy, arylalkyl, aryloxyalkyl, cycloalkyl, cycloakylamino, (cycloalkyl)alkenyl, (cycloalkyl)alkyl, cycloalkyloxyalkyl, haloalkyl, alkylheterocyclyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkoxy, heterocyclylalkyl, heterocyclyloxyalkyl, and hydr
A · US 9,932,326 B2 · ¶ 30
1.10each RE is independently selected from: (i) hydroxyl
1.11(ii) C1-C6 alkoxy, (iii) phenyl optionally substituted with 1-3 substituents selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxyalkyl, C1-C6 alkoxy, hydroxyl, cyano, and halogen, (iv) 5-10 membered heteroaryl optionally substituted with C1-C6 alkyl, and (v) C3-C10 cycloalkyl
1.12Q is selected from: (i) C1-C6 hydroxyalkyl, (ii) —C(═O)OH, (iii) —S(═O)2OH, (iv) cyano, (v) —S(O)2NRA1RB1, (vi) —NRCS(O)2NRA1RB1, (vii) —C(═O)C1-C6 alkoxy optionally substituted with C1-C6 alkoxy optionally substituted with —S(═O)2NRCRD or 5-6 membered heterocyclyl optionally substituted with C1-C6 alkyl (viii) —C(═O)C6-C10 aryloxy (ix) —C(═O)-(5-6 membered heterocyclyloxy) optionally substituted with 1-4 substituents selected from C1-C6 alkyl, hydroxyl, and —C(═O)OH, (x) —C(═O)NRA2RB2, (xi) C1-C6 haloalkyl optionally substituted with hydroxyl, (xii) 5-6 membered heteroaryl optionally substituted with hydroxyl, and (xiii) —C(═O)NHS(═O)2RF X is selected from —(CH2)xNRGC(═O)O—, —(CH2)xOC(═O)NRG—, —(CH2)xNRG, or —CH(OH)— RA1 and RB1 are independently selected from hydrogen and C1-C6 alkyl optionally substituted with hydroxyl RA2 and RB2 are independently selected from hydrogen and C1-C6 alkyl optionally substituted with hydroxyl or —S(═O)2NH2 RC and RD are independently selected from hydrogen and C1-C6 alkyl RF is selected from: (i) C1-C6 alkyl optionally substituted with 1-3 substituents selected from: (a) hydroxyl, (b) halogen, (c) cyano, (d) C1-C6 alkoxy, (e) 4-6-membered heterocyclyl optionally substituted with C1-C6 alkyl, (f) —C(═O)OH, (g) —OC(═O)C1-C6 alkyl, (h) —S(═O)2C1-C6 alkyl, (i) —C(═O)NRA1RB1, (j) —NRCRD, (k) —C(═O)C1-C6 aryloxy, (l) C3-C6 cycloalkyl optionally substituted with —C(═O)OH, C1-C6 hydroxyalkyl, —C(═O)NRA1RB1, or —C(═O)C1-C6 alkoxy, and (m) —C(═O)C1-C6 alkoxy optionally substituted with —C(═O)C1-C6 alkyl or —OC(═O)C1-C6 alkyl, (ii) C2-C6 alkenyl, (iii) C1-C6 haloalkyl, (iv) phenyl, (v) C3-C6 cycloalkyl optionally substituted with (a) C1-C6 alkyl optionally substituted with 1-3 substituents selected from hydroxyl, —C(═O)OH, —C(═O)NRA1RB1, or —C(═O)C1-C6 alkoxy, (b) cyano, (c) —C(═O)OH, (d) —C(═O)NRCRD, or (e) —C(═O)C1-C6 alkoxy optionally substituted with hydroxyl or —C(═O)C1-C6 alkyl, or (f) —NRCRD, and (vi) —NRA3RB3 RA3 and RB3 are independently selected from hydrogen and C1-C6 alkyl RG is H or C1-C3 alkyl x is 0 or 1.
R14 and R14′ are, independently, H, halogen, hydroxy, C1-6 alkoxy, aryl, 5-membered heteroaryl, C1-6 alkyl or halo substituted aryl, aryl or halo substituted 5-membered heteroaryl, cyano, C2-6 alkynyl, C3-6 alkoxyalkyl, alkoxycarbonylalkyl, heterocyclylalkyl, or hydroxyalkyl; and R15 and R15′ are, independently, hydrogen, C2-6 alkoxy, C3-6 alkoxyalkyl, alkoxycarbonyl, carbonylalkyl, carbonyl aryl, C1-6 alkyl, heterocyclylalkyl, or C2-6 hydroxyalkyl, Z is C1-6 alkyl, alkenyl,
A · US 9,932,326 B2 · claim 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
Therefore, there is an urgent need for new HCV drugs.
A · US 9,932,326 B2 · ¶ 3
The present invention provides compounds, methods and compositions for treating or preventing HCV infection in a host.
A · US 9,932,326 B2 · ¶ 7
However for many other applications, the need exists for new photoresists that can provide highly resolved images of submicron dimension.
B · US 10,179,778 B2 · ¶ 3
We have now discovered new acid generators and photoresist compositions that comprise one or more of such acid generators.
B · US 10,179,778 B2 · ¶ 6
Cite aspatent.fyi, US 2026/0356824 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356824/, SHA-256 dd2eb4ff8827b59157be054ddc8d3751fb93e64c74ebbfa25c11e68a8d97b135
First published
Permanent addresshttps://patent.fyi/US20260356824/
Content fingerprint (SHA-256)dd2eb4ff8827b59157be054ddc8d3751fb93e64c74ebbfa25c11e68a8d97b135
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi